By: Frank Lotthrincx, Sofyan El Boujjoufi
25 Sep 2026 2 min read
We are happy to provide you with new (international) insights in the areas of finance, business operations, strategy, governance, risk, compliance and more.
When revenue is limited and investments depend on research outcomes, the cash runway largely determines a company’s strategic flexibility.
That calls for answers to questions such as:
According to recent third‑party market research, a significant share of biotech companies find themselves in a challenging funding environment. An increasing number of businesses have less than one year of cash runway. At the same time, management teams are expected to focus more sharply on capital allocation and to define clearer milestones. As a result, the focus is shifting from growth at any cost to controlled and sustainable growth.
A good forecast is not just a financial document. It is an important decision‑making tool. Strong organisations link their financial forecasts to:
It is precisely this connection between operational progress and financial consequences that makes a forecast valuable.
Investors, grant providers and other stakeholders accept uncertainty. What they accept less is a lack of understanding of that uncertainty. Up‑to‑date forecasts, scenario analyses and transparent assumptions make risks negotiable and strengthen confidence in the company.
Cash runway is not just about cutting costs. It’s about creating room for action. Organisations that gain earlier insight into future financing needs can invest more strategically, respond more swiftly to change and engage with financiers and investors with greater confidence.
Would you like to discuss these insights further? Get in touch with us.
For many life sciences companies, financing is not a one-off event but a recurring part of their growth strategy. New investments are needed to reach the next development phase, and at the same time, that very progress determines investor confidence.
